InCarda

View All

Pharma news fro GSK, InCarda, BridgeBio
GSK’s RSV vaccine; SparingVision’s interest in gene therapy; InCarda’s raise; BridgeBio’s R&D deal

GSK eyes robust immune response from RSV vaccine  Cold viruses mostly do not get much attention in terms of R&D. They usually make humans feel miserable for a few days, and later than clear up. However, some cold viruses can hit vulnerable people much harder, which leads to pneumonia and hospitalizations. Th...

Find More